Your session is about to expire
← Back to Search
Unknown
FDY-5301 for Heart Attack (IOCYTE AMI-3 Trial)
Phase 3
Waitlist Available
Research Sponsored by Faraday Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 18 years
Planned primary PCI to occur ≤ 6 hours of onset of first symptoms of myocardial ischemia
Must not have
Renal disease requiring dialysis
Life expectancy of less than 1 year due to non-cardiac pathology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through month 12
Awards & highlights
Pivotal Trial
Summary
This trial is testing a new drug called FDY-5301 to see if it can help people who have had a severe heart attack. It focuses on patients undergoing a procedure to open blocked arteries and aims to improve their recovery and reduce complications.
Who is the study for?
This trial is for adults over 18 with a specific type of heart attack called anterior STEMI, who can get treatment within 6 hours. It's not for those with life-threatening non-cardiac issues, pregnant or breastfeeding women, people on recent investigational drugs, thyroid disease patients, iodine allergy sufferers, individuals on dialysis, or anyone over 309 lbs.
What is being tested?
The study tests if FDY-5301 reduces death from heart problems and acute heart failure in patients having a procedure to open blocked arteries after a severe type of heart attack. Participants will either receive FDY-5301 or a placebo without knowing which one they're getting.
What are the potential side effects?
Specific side effects of FDY-5301 are not listed here but could include reactions related to the cardiovascular system given the nature of the drug and patient population. Placebos typically have no active ingredients but can cause side effects due to psychological factors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am scheduled for a heart procedure within 6 hours of my first chest pain.
Select...
I had a heart attack in the front part of my heart with specific ECG changes.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am on dialysis for kidney failure.
Select...
My doctor expects I have less than 1 year to live due to a non-heart related condition.
Select...
I am not pregnant or breastfeeding, and I have a negative pregnancy test.
Select...
My weight is over 309 lbs.
Select...
I have a thyroid condition or am on thyroid medication.
Select...
I received clot-dissolving medication for my heart attack.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through month 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through month 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of either cardiovascular mortality or heart failure
Secondary study objectives
All-cause mortality or acute heart failure
Cardiovascular events
Other non-fatal cardiovascular morbidity
+1 moreSide effects data
From 2019 Phase 2 trial • 120 Patients • NCT034704417%
Constipation
7%
Cardiac failure
7%
Haematoma
7%
Atrial fibrillation
3%
Acute myocardial infarction
3%
Liver function test abnormal
3%
Coronary artery dissection
3%
Vascular stent thrombosis
3%
Cardiac ventricular thrombosis
3%
Ischaemic stroke
3%
Chest pain
3%
Colitis
3%
Gastroduodenitis
3%
Delirium
3%
Diarrhoea
3%
Dizziness
3%
Coronary artery disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
Experimental FDY-5301 Low Dose
Experimental FDY-5301 Intermediate Dose
Experimental FDY-5301 High Dose
Placebo
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: FDY-5301Experimental Treatment1 Intervention
FDY-5301 will be administered as a single IV bolus injection.
Group II: PlaceboPlacebo Group1 Intervention
Placebo (normal saline) will be administered as a single IV bolus injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDY-5301
2017
Completed Phase 2
~120
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for heart attacks include antiplatelet agents, anticoagulants, thrombolytics, and beta-blockers. Antiplatelet agents like aspirin and clopidogrel prevent platelets from clumping, reducing clot formation.
Anticoagulants such as heparin inhibit clotting factors to prevent new clots. Thrombolytics like tissue plasminogen activator (tPA) dissolve existing clots to restore blood flow.
Beta-blockers reduce heart rate and blood pressure, decreasing the heart's oxygen demand. These treatments are crucial for heart attack patients as they help restore and maintain blood flow to the heart, reduce the risk of further cardiac events, and improve survival.
Find a Location
Who is running the clinical trial?
Faraday Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
128 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I am on dialysis for kidney failure.I am scheduled for a heart procedure within 6 hours of my first chest pain.My doctor expects I have less than 1 year to live due to a non-heart related condition.I am not pregnant or breastfeeding, and I have a negative pregnancy test.My weight is over 309 lbs.I have a thyroid condition or am on thyroid medication.I received clot-dissolving medication for my heart attack.You are allergic to iodine.I had a heart attack in the front part of my heart with specific ECG changes.
Research Study Groups:
This trial has the following groups:- Group 1: FDY-5301
- Group 2: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.